The Medical Advisor

Executive Summary Cancer incidence is increasing for certain age groups and cancer types, especially among younger adults , but the reasons are complex and multifactorial: Cancer statistics from major registries (SEER and global data) show that some cancers (e.g., colorectal, thyroid, breast) have increased in younger adults over recent decades. ( PubMed ) Chronic inflammation and immune dysregulation are recognized contributors to cancer development, but they do not act in isolation and are not proven to be the single cause of rising cancer incidence. ( MDPI ) Lifestyle factors such as obesity, poor diet, smoking, and sedentary behavior are established contributors to cancer risk.  Emerging research continues to explore links between immune markers and cancer prognosis, but there is no strong evidence that infections like COVID-19 or vaccines cause cancer. ( Springer Nature Link ) Cancer prevention strategies supported by evidence include vaccination against oncogenic viruses (e...

Brain cancer, particularly aggressive forms like glioblastoma multiforme (GBM), remains one of the most formidable challenges in oncology, with limited treatment options, high recurrence rates, and dismal survival prognoses despite advances in surgery, chemotherapy, and radiation.  In recent years, however, a paradigm shift has emerged through the repurposing of established antiparasitic medications—ivermectin and mebendazole—as potential adjunctive therapies. These drugs, long proven safe for human use against parasitic infections, are now drawing attention for their anticancer properties, including the ability to target cancer stem cells, disrupt tumor metabolism, and cross the blood-brain barrier to combat intracranial malignancies.  Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2025, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and ...